Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Core Viewpoint - The Nipah virus outbreak in India has prompted several A-share listed companies, including BGI Innovation, Capbio, and Antu Biology, to announce their capabilities in Nipah virus testing, although they have not yet achieved significant revenue from these products [1] Group 1: Company Responses - Antu Biology stated that the demand for its Nipah virus testing products cannot be estimated at this early stage of the outbreak in India, and its overseas market presence is relatively small [1] - Capbio acknowledged its technical capability to detect the Nipah virus, but indicated that commercialization is not yet underway and will require time to implement outside of emergency situations [1]

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].

Group 1 - The core viewpoint of the news is that Antu Biology's stock has increased by 5.98%, reaching a price of 39.54 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 22.594 billion yuan [1] - Antu Biology, established on September 15, 1999, and listed on September 1, 2016, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 86.63% from reagents, 10.99% from instruments, 1.40% from other sources, and 0.98% from maintenance income [1] - Changjiang Asset Management holds a significant position in Antu Biology through its fund, Changjiang Xuri Mixed A (021015), which held 71,000 shares in the fourth quarter, accounting for 2.47% of the fund's net value, ranking as the tenth largest holding [1] Group 2 - The fund manager of Changjiang Xuri Mixed A (021015) is Shi Zhan, who has been in the position for 4 years and 30 days, with the fund's total asset size being 802 million yuan [2] - During Shi Zhan's tenure, the best fund return was 53.53%, while the worst return was 48.76% [2]

Group 1 - The Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers, with nearly 100 individuals under home quarantine [1][2] - The virus has a high fatality rate of over 40%, with some reports indicating rates as high as 75%, and there is currently no effective vaccine or treatment available [2][3] - The outbreak has prompted heightened public health alerts globally, with neighboring countries like Thailand and Nepal increasing their screening and quarantine measures for travelers from India [3] Group 2 - The A-share market saw a surge in stocks related to influenza, virus testing, and vaccines, with several companies hitting their daily price limits [1][4] - Companies like Zhijiang Biology and Hualan Vaccine confirmed they have relevant products but currently lack orders from India, while others like Antu Biology and Shuoshi Biology are actively promoting their technical capabilities in response to the outbreak [4][5] - Some vaccine companies, such as Jindike, have stated they do not have any products related to the Nipah virus, indicating a divergence in market reactions among different sectors [5][6]

郑州安图生物工程股份有限公司为规避汇率波动风险，拟使用不超过8,900万美元的自有资金开展外汇 套期保值业务，交易品种包括远期结售汇、外汇掉期、外汇期权等，交易期限自董事会审议通过之日起 12个月内有效。公司已制定相关管理制度，明确业务以实际经营为基础，禁止投机交易，并采取多项风 险防控措施。该事项旨在降低汇兑损失，增强财务稳健性，符合公司发展需要。 截至2026年1月23日收盘，安图生物（603658）报收于37.31元，较上周的36.89元上涨1.14%。本周，安 图生物1月19日盘中最高价报37.39元。1月19日盘中最低价报36.61元。安图生物当前最新总市值213.2亿 元，在医疗器械板块市值排名10/127，在两市A股市值排名1012/5182。 本周关注点 公司公告汇总 安图生物第五届董事会第十次会议决议公告 郑州安图生物工程股份有限公司于2026年1月20日召开第五届董事会第十次会议，审议通过《关于开展 外汇套期保值业务的议案》和《关于向金融机构申请贷款的议案》。会议应到董事12名，实际参与表决 12名，所有议案均获全票通过。公司拟向金融机构申请不超过人民币15亿元的贷款，用于日常经营及发 展 ...

证券代码：603658 证券简称：安图生物 公告编号：2026-003 郑州安图生物工程股份有限公司 第五届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 全体董事均出席本次董事会。 登录新浪财经APP 搜索【信披】查看更多考评等级 ● 无董事对本次董事会议案投反对/弃权票。 ● 本次董事会全部议案均获通过。 一、董事会会议召开情况 郑州安图生物工程股份有限公司（以下简称"安图生物"或"公司"）第五届董事会第十次会议的会议通知 和材料于2026年1月16日以电子邮件方式发出，会议于2026年1月20日在公司会议室以现场和通讯相结合 的方式召开，会议应参加董事12名，实际参加表决董事12名（其中董事张亚循先生、付光宇先生、冯超 姐女士，独立董事乔海灵先生、申香华女士、袁华刚先生以通讯方式参会；董事刘微女士以委托方式参 会）。会议由公司董事长苗拥军先生主持，公司部分高级管理人员列席了本次会议。 会议的召集和召开程序符合《公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》 ...

截至2026年1月20日收盘，安图生物(603658)报收于36.89元，下跌0.54%，换手率0.38%，成交量2.15万 手，成交额7929.77万元。 当日关注点 交易信息汇总资金流向 1月20日主力资金净流出1300.16万元；游资资金净流入525.65万元；散户资金净流入774.52万元。 关于开展外汇套期保值业务的可行性分析报告 郑州安图生物工程股份有限公司为规避汇率波动风险，拟使用不超过8,900万美元的自有资金开展外汇 套期保值业务，交易品种包括远期结售汇、外汇掉期、外汇期权等，交易期限自董事会审议通过之日起 12个月内有效。公司已制定相关管理制度，明确业务以实际经营为基础，禁止投机交易，并采取多项风 险防控措施。该事项旨在降低汇兑损失，增强财务稳健性，符合公司发展需要。 安图生物关于开展外汇套期保值业务的公告 郑州安图生物工程股份有限公司于2026年1月20日召开第五届董事会第十次会议，审议通过开展外汇套 期保值业务的议案，期限为2026年1月20日至2027年1月19日。公司及控股子公司拟使用不超过8,900万 美元（含等值外币）的自有资金，开展远期结售汇、外汇掉期、外汇期权、利率互换等外 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关于开展外汇套期保值业务的可行性分析报告》 《安图生物关于开展外汇套期保值业务的公告》 《安图生物第五届董事会第十次会议决议公告》 近日，安图生物发布关于开展外汇套期保值业务的公告。根据公告内容，公司于2026年1月20日召开第 五届董事会第十次会议，审议通过开展外汇套期保值业务的议案，期限为2026年1月20日至2027年1月19 日。公司及控股子公司拟使用不超过8,900万美元（含等值外币）的自有资金，开展远期结售汇、外汇 掉期、外汇期权、利率互换等外汇衍生品交易，以规避汇率波动风险，不进行投机和非法套利交易。该 事项无需提交股东大会审议。 最新公告列表 截至2026年1月20日收盘，安图生物（603658）报收于36.89元，较前一交易日下跌0.54%，最新总市值 为210.8亿元。该股当日开盘37.09元，最高37.24元，最低36.8元，成交额达7929.77万元，换手率为 0.38%。 ...